NDAORALTABLET
Approved
Jun 1939
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Butabarbital sodium is a barbiturate sedative-hypnotic agent approved in 1939 for oral use as a tablet. It belongs to an older class of CNS depressants historically used for anxiety, insomnia, and sedation. The drug acts as a barbiturate by enhancing GABA-mediated inhibition in the central nervous system.
LOE Approaching
As a legacy product approaching loss of exclusivity with minimal contemporary data, this asset likely operates with a small, maintenance-focused commercial team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Butisol Sodium offers minimal career advancement opportunities due to the product's approaching loss of exclusivity, legacy status, and declining clinical relevance. Roles on this asset are suited for professionals seeking stable, low-stress operational work rather than dynamic commercial or innovation-focused positions.
Regulatory AffairsCompliance Officer
Worked on BUTISOL SODIUM at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.